Jul 1, 2009
By:Ophthalmology Times Staff Reports
Software (MatchedFlicker, EyeIC) that monitors the advent and progression of glaucoma through retinal photography has received FDA 510(k) clearance.
 |
Jul 1, 2009
By:Ophthalmology Times Staff Reports
The FDA has approved dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion.
|
Jul 1, 2009
By:Ophthalmology Times Staff Reports
The FDA has granted 510(k) clearance for an injector system (Epiphany, STAAR Surgical Co.) designed for use with a three-piece new-technology IOL ([NTIOL]; Affinity Collamer, STAAR Surgical) and a silicone NTIOL (Elastimide, STAAR Surgical), according to the devices' manufacturer.
|
Topical ophthalmic fluoroquinolone treats broad range of bacterial ocular pathogens
Jul 1, 2009
By:Jennifer A. Webb
Besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb) is a new topical ophthalmic antibacterial indicated for the treatment of bacterial conjunctivitis and administered via sterile ophthalmic drops.
|
Jul 1, 2009
By:Ophthalmology Times Staff Reports
The Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the FDA has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals Inc.) as an eye-drop treatment for ocular itching associated with allergic conjunctivitis, according to the company.
|
Jul 1, 2009
By:Jennifer A. Webb
The FDA has given 501(k) clearance to the TearLab Osmolarity System, a new device that measures the osmolarity of tears to aid in the diagnosis of dry eye disease.
|
Jun 22, 2009
Omega-3 fatty acids found in fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD).
|
Jun 18, 2009
Dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan), indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), has been approved by the FDA. Retinal vein occlusion including BRVO and CRVO is the second most common retinal vascular disease after diabetic retinopathy.
|
Jun 17, 2009
Researchers identified a biological marker, CCR3, which is linked to the development and progression of neovascular age-related macular degeneration (AMD).
|
| 
